Back to News
Market Impact: 0.42
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
Source: businesswire.com
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The FDA approved Merck's WELIREG in combination with Eisai's LENVIMA for certain previously treated adults with advanced renal cell carcinoma containing a clear-cell component. The approval expands the available treatment options in advanced kidney cancer and creates a new commercial opportunity for the WELIREG-LENVIMA regimen.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.82
Ticker Sentiment
MRK0.85
More News
- H.C. Wainwright raises Surrozen stock price target on Wnt pathway validation
- OpenAI rogue agents leaked 53 images from ChatGPT users and reportedly created nearly 1 million links packing encoded bits of info
- Facebook found liable as TikTok settles for $100m over user safety
- What would a US diesel export ban mean for global fuel prices?
- US court rules against Kalshi, says states can regulate prediction markets
- Appeals court rules that states can regulate Kalshi’s sports prediction markets, dealing another legal blow to platforms
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- AI Software for Buy-Side Teams: Build the Research Stack